Margaret M. Johnson

Margaret M. Johnson

Auto-generated profile, based on publicly available information

Margaret M. Johnson

Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, Florida

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014
Verified
Journal Article
Open access
PDF file
MJMargaret M. Johnson
Margaret M. Johnson
JOJohn A. Odell
John A. Odell
Nontuberculous mycobacterial pulmonary infections

14 September 2022 in Respirology
Verified
Journal Article
Closed access
ALAlejandra Yu Lee‐Mateus
Alejandra Yu Lee‐Mateus
JRJanani Reisenauer
Janani Reisenauer
JGJuan C. Garcia‐Saucedo
Juan C. Garcia‐Saucedo
DADavid Abia-Trujillo
David Abia-Trujillo
EBEeeLN H. Buckarma
EeeLN H. Buckarma
SFSebastian Fernandez‐Bussy
Sebastian Fernandez‐Bussy

1 February 2015 in Journal of Critical Care
Verified
Journal Article
Closed access
LKLioudmila V. Karnatovskaia
Lioudmila V. Karnatovskaia
MJMargaret M. Johnson
Margaret M. Johnson
RBRoberto P. Benzo
Roberto P. Benzo
OGOgnjen Gajic
Ognjen Gajic

1 July 2024 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
TATimothy R. R Aksamit
Timothy R. R Aksamit
NLNicholas Locantore
Nicholas Locantore
DADoreen Addrizzo-Harris
Doreen Addrizzo-Harris
JAJuzar Ali
Juzar Ali
ABAlan Barker
Alan Barker
BZBeth Shoshanna Zha
Beth Shoshanna Zha
Rationale: Nontuberculous mycobacteria (NTM) are prevalent among patients with bronchiectasis. However, the long-term natural history of patients with NTM and bronchiectasis is not well described. Objectives: To assess the impact of NTM on 5-year clinical outcomes and mortality in patients with bronchiectasis. Methods: Patients in the Bronchiectasis and NTM Research Registry with ⩾5 years of follow-up were eligible. Data were collected for all-cause mortality, lung function, exacerbations, hospitalizations, and disease severity. Outcomes were compared between patients with and without NTM at baseline. Mortality was assessed using Cox proportional hazards models and the log-rank test. Measurements and Main Results: In total, 2,634 patients were included: 1,549 (58.8%) with and 1,085 (41.2%) without NTM at baseline. All-cause mortality (95% confidence interval) at Year 5 was 12.1% (10.5%, 13.7%) overall, 12.6% (10.5%, 14.8%) in patients with NTM, and 11.5% (9.0%, 13.9%) in patients without NTM. Independent predictors of 5-year mortality were baseline FEV1 percent predicted, age, hospitalization within 2 years before baseline, body mass index, and sex (all P < 0.01). The probabilities of acquiring NTM or Pseudomonas aeruginosa were approximately 4% and 3% per year, respectively. Spirometry, exacerbations, and hospitalizations were similar, regardless of NTM status, except that annual exacerbations were lower in patients with NTM (P < 0.05). Conclusions: Outcomes, including exacerbations, hospitalizations, rate of loss of lung function, and mortality rate, were similar across 5 years in patients with bronchiectasis with or without NTM.

1 March 2018 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
MMMark L Metersky
Mark L Metersky
TATimothy R. R Aksamit
Timothy R. R Aksamit
ABAlan Barker
Alan Barker
RCRadmila Choate
Radmila Choate
CDCharles L. Daley
Charles L. Daley
DMDavid Mannino
David Mannino
Rationale: Staphylococcus aureus is commonly cultured from the sputum of patients with bronchiectasis; however, little is known about the prevalence of the organism in these patients, the characteristics of patients who have grown the organism, or its implications. Objectives: Determine the relationship between S. aureus and pulmonary function, frequency of exacerbations, and frequency of hospitalization in patients with bronchiectasis Methods: The Bronchiectasis Research Registry is a database of adults with non–cystic fibrosis bronchiectasis identified from 13 sites within the United States. Baseline and follow-up demographic, spirometric, microbiologic, and therapeutic data were entered into a central web-based database. Patients were grouped into three cohorts based on their previous respiratory cultures at the time of entry into the Registry: 1) no prior S. aureus or glucose-nonfermenting gram-negative bacilli (NF-GNB) (Pseudomonas, Stenotrophomonas, or Burkholderia spp.); 2) prior S. aureus at least once; or 3) no prior S. aureus but prior NF-GNB at least once. The association between S. aureus isolation and pulmonary function and frequency of exacerbations and hospital admissions was assessed, both at baseline and after 1 year of follow-up. Results: S. aureus was cultured from 94 of 830 patients (11.3%) included in the analysis. Patients who had grown S. aureus before entry into the Registry had a frequency of prior exacerbations and baseline pulmonary function that was between that of patients who had grown NF-GNB and those who had grown neither NF-GNB or S. aureus. Similarly, at the first follow-up visit after study entry, patients who had grown S. aureus had a frequency of exacerbations and hospitalizations that was between those of patients who had grown NF-GNB and those who had grown neither NF-GNB nor S. aureus. However, in multivariate analysis, S. aureus was not associated with pulmonary function, frequency of exacerbation, or hospital admissions. There were no significant differences in patient characteristics or outcomes between patients who had methicillin-sensitive and methicillin-resistant S. aureus. Conclusions: Staphylococcus aureus does not appear to be an independent risk factor for severe disease in patients with bronchiectasis enrolled in the Bronchiectasis Research Registry.

1 June 2004 in Clinics in Chest Medicine
Verified
Journal Article
Closed access
MJMargaret M Johnson
Margaret M Johnson